# (PART) SPECIFIC KIDNEY DISEASES {-}

# Glomerular disease

## Proteinuria

[**Svenningsen et al.**](https://www.ncbi.nlm.nih.gov/pubmed/19073825) (2009): ![](Logo_PHY.png){height=1.2em} - activation of ENaC by proteolytic enzymes drives oedema in nephrotic syndrome.  


## IgAN
\BeginKnitrBlock{box_landmark}<div class="box_landmark">[**STOP-IgAN**](https://www.ncbi.nlm.nih.gov/pubmed/26630142) (2015): ![](Logo_RCT.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - supportive care only *vs.* immunosuppression in IgAN with PER > 0.75 g/day.  No difference in renal outcomes (in 3-year follow-up) but more adverse events in immunosuppression group.    
</div>\EndKnitrBlock{box_landmark}

[**TESTING**](https://www.ncbi.nlm.nih.gov/pubmed/28763548) (2017): ![](Logo_RCT.png){height=1.2em} - oral methylprednisolone *vs.* placebo in IgAN with PER > 1 g/day.  Trial terminated prematurely due to excess of adverse events in the steroid group.  

## Membranous 

\BeginKnitrBlock{box_landmark}<div class="box_landmark">[**Beck et al**](https://www.ncbi.nlm.nih.gov/pubmed/19571279) (2009): ![](Logo_PHY.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - description of PLA2R autoantibodies in membranous nephropathy.  

[**MRC Membranous**](https://www.ncbi.nlm.nih.gov/pubmed/23312808) (2013): ![](Logo_RCT.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - prednisolone & chlorambucil *vs.* CsA *vs.* supportive care in primary membranous nephropathy.  Rate of renal decline was slower in the prednisolone & chlorambucil group.  
</div>\EndKnitrBlock{box_landmark}

[**MENTOR**](https://www.ncbi.nlm.nih.gov/pubmed/31269364) (2019): ![](Logo_RCT.png){height=1.2em} - rituximab vs. oral CsA in iMN with CrCl \> 40 ml/min and PER > 5g/day.  Primary outcome of complete or partial remission of proteinuria by 24 months was acheived in 60% of RTX group and 20% of CsA group.  

## Minimal change
[**MinTAC**](https://cjasn.asnjournals.org/content/early/2020/01/16/CJN.06180519) (2020): ![](Logo_RCT.png){height=1.2em} - tacrolimus *vs* prednisolone monotherapy in adult MCD.  Tacrolimus non-inferior wrt primary outcome of inducing complete remission by 8 weeks.  ~90% in either group entered remission by 6 months; ~70% in each group relapsed.  


<!-- see also [UKKW 2019](http://www.ukkw.org.uk/wp-content/uploads/2019/08/O334.pdf)-->

## FSGS

[**Savin et al.**](https://www.ncbi.nlm.nih.gov/pubmed/8596570) (1996): ![](Logo_PHY.png){height=1.2em} - patients with recurrent FSGS after transplant have a circulating factor that could increase glomerular permeablity in an *in vitro* assay.  

## APOL1 nephropathy {#Apol1}

[**Parsa et al.**](https://www.ncbi.nlm.nih.gov/pubmed/24206458) (2013): ![](Logo_OBS.png){height=1.2em} - APOL1 risk variants were associated with accelerated progression of CKD in the AASK and CRIC study cohorts.  

## aHUS

[**Legendre et al.**](https://www.ncbi.nlm.nih.gov/pubmed/23738544) (2013): ![](Logo_OBS.png){height=1.2em} - recovery of renal function and freedom from TMA events observed in eculizumab-treated aHUS.  
